Related Experiment Video
Updated: May 6, 2026

Setup of Capillary Electrophoresis-Inductively Coupled Plasma Mass Spectrometry CE-ICP-MS for Quantification of Iron Redox Species FeII, FeIII
Published on: May 4, 2020
Manganese in human parenteral nutrition: considerations for toxicity and biomonitoring
Dinamene Santos1, Camila Batoreu1, Luisa Mateus1
1I-Med.UL, Department of Toxicology and Food Sciences, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
Abstract:
The iatrogenic risks associated with excessive Mn administration in parenteral nutrition (PN) patients are well documented. Hypermanganesemia and neurotoxicity are associated with the duration of Mn supplementation, Mn dosage, as well as pathological conditions, such as anemia or cholestasis. Recent PN guidelines recommend the biomonitoring of patients if they receive Mn in their PN longer than 30 days. The data in the literature are conflicting about the method for assessing Mn stores in humans as a definitive biomarker of Mn exposure or induced-neurotoxicity has yet to be identified. The biomonitoring of Mn relies on the analysis of whole blood Mn (WB Mn) levels, which are highly variable among human population and are not strictly correlated with Mn-induced neurotoxicity. Alterations in dopaminergic (DAergic) and catecholaminergic metabolism have been studied as predictive biomarkers of Mn-induced neurotoxicity. Given these limitations, this review addresses various approaches for biomonitoring Mn exposure and neurotoxic risk.
Insights
Excessive manganese (Mn) in parenteral nutrition (PN) can cause neurotoxicity. Current biomonitoring methods for Mn exposure are unreliable, necessitating better approaches for patient safety.
Area of Science:
- Clinical Chemistry
- Neurotoxicology
- Nutritional Science
Background:
- Iatrogenic risks of excessive manganese (Mn) in parenteral nutrition (PN) are known.
- Hypermanganesemia and neurotoxicity link to Mn dose, duration, and patient conditions like anemia or cholestasis.
- Current PN guidelines suggest biomonitoring for Mn after 30 days of supplementation.
Purpose of the Study:
- To review current approaches for biomonitoring Mn exposure.
- To assess methods for evaluating Mn-induced neurotoxic risk in PN patients.
- To address limitations in existing Mn biomonitoring strategies.
Main Methods:
- Literature review of studies on Mn biomonitoring.
- Analysis of conflicting data regarding Mn biomarkers.
- Examination of dopaminergic (DAergic) and catecholaminergic metabolism alterations as potential biomarkers.
Main Results:
- No definitive biomarker for Mn exposure or neurotoxicity has been identified.
- Whole blood Mn (WB Mn) levels are variable and not strictly correlated with neurotoxicity.
- Alterations in DAergic and catecholaminergic metabolism show potential as predictive biomarkers.
Conclusions:
- Existing methods for Mn biomonitoring in PN patients have significant limitations.
- Further research is needed to identify reliable biomarkers for Mn exposure and neurotoxicity.
- Improved biomonitoring is crucial for managing Mn risks in PN patients.
More Related Videos
Related Concept Videos
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Microbes and Other Elemental Cycles
Drug Toxicity: Risk factors
Drug Toxicity: Overview
The Periodic Table and Organismal Elements
Periodic Table Provides Information...
The Periodic Table and Organismal Elements

